This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The product will be manufactured at Lupin’s Somerset facility in the US
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Granules now has a total of 67 ANDA approvals from the USFDA
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Subscribe To Our Newsletter & Stay Updated
